Platelets in Rheumatic Diseases: Friend or Foe?

摘要: Platelets are intimately involved in hemostasis, inflammation, innate and adaptive immunity, tissue regeneration other physiological pathological processes. Their granular structure is programmed to release a wide range of bioactive substances response agonists. Upon activation, platelet membranes display thrombotic inflammatory agents, which may take an active part the pathophysiology autoimmune autoinflammatory disorders. The aim this review analyze current evidence (dys)function rheumatic diseases overview platelettargeting mechanisms antirheumatic drug therapies. A comprehensive search through Medline/PubMed, SciVerse/Scopus Web Science was performed for English-language original research papers, using keywords related platelets Additionally, Cochrane Collaboration database searched literature on effects drugs function. variety markers have been tested systemic lupus erythematosus, rheumatoid arthritis, sclerosis, spondyloarthropathies, vasculitides, some It has shown that circulate activated state most these disorders tend form complexes with immune cells. Thrombotic released from platelets, trigger disease-specific complications (e.g., extraarticular features, fibrosis sclerosis) propagate endothelial dysfunction. Whether activation primary or secondary feature remains be elucidated. Some widely used suppress thrombopoiesis activity, however clinical implications effect yet examined specifically designed prospective studies. Large retrospective cohort studies supported use low-dose aspirin suppressing function preventing cerebrovascular events giant-cell arteritis. However, emerging data suggest rate applied topically inflamed cartilage arthritis skin ulcers scleroderma inflammation facilitate repair. Taken together, necessitates balanced approach platelet-activating therapies diseases.